Anti-EGFRvIII chimeric antigen receptor T cell therapy - Suzhou Maximum Biotech
Alternative Names: Anti-EGFRvIII CAR T cell therapy - Suzhou Maximum Biotech; EGFRvIII CAR-T cell therapy - Suzhou Maximum Bio-techLatest Information Update: 28 Dec 2022
At a glance
- Originator Suzhou Maximum Bio-tech
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioma
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Glioma(Late-stage disease) in China (IV, Infusion)
- 15 Feb 2019 Suzhou Maximum Biotech plans a phase I trial for Glioma (Late-stage disease) in China (ChiCTR1900020829 )